Nov 29, 2022 · D3S-001 is a selective and covalent KRAS G12C small molecule inhibitor designed to enhance KRAS G12C target engagement. In preclinical investigation, D3S-001 …

D3S-001 is a next-generation KRAS G12C inhibitor designed to enhance clinical outcomes by improving KRAS G12C target engagement. In preclinical investigations, D3S-001 has …

Shanghai, China, Sep 12, 2024 — D3 Bio today announced that it will present clinical data from its lead oncology program, D3S-001, a second-generation KRAS G12C inhibitor with best-in …

Today, D3 Bio announced that the company received IND (Investigational New Drug) clearance from US FDA for D3S-001, a potent and selective small molecule inhibitor for the mutant …

Today, D3 Bio announced that the company received IND (Investigational New Drug) clearance from US FDA IND for D3S-001, a potent and selective small molecule inhibitor for the mutant …

Mar 31, 2023 · The Company received Orphan Drug Designation (ODD) from Office of Orphan Products Development (OOPD), FDA, to D3S-001 for treatment of patients with advanced …

Oct 31, 2022 · D3S-001 is a small molecule inhibitor that selectively and irreversibly inhibits the KRAS G12C mutant protein, blocking its interaction with downstream effectors, such as the …

D3L-001, for treatment of eligible patients with locally advanced or metastatic HER2-positive breast cancer. The purpose of this policy is to describe the requirements for Expanded Access …

The funding will be allocated to expedite the development of D3 Bio's assets through preclinical and clinical stages, with a particular focus on accelerating the global clinical trial of D3S-001, a …